Stock LYRA LYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.3255 USD -0.18% Intraday chart for Lyra Therapeutics, Inc. -15.01% -93.79%
May. 21 Lyra Therapeutics Reduces Workforce to Extend Cash Runway MT
May. 21 Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital CI

Evolution of the average Target Price on Lyra Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8007474bf20dcebe330e93d68aade2b6.fzZZUn8qpBHcqZ_GY1Wv0sn6TzILYGK-atk7xYa643g.OEEvDTRJ1im_5_D0LhLf4aqPIGRFCAzIG65ikfSDpBFNbxhjRnP8a6jipw~04ff6cc32e8f4bcd942a3ef6c22594cd

Analyst Recommendations on Lyra Therapeutics, Inc.

Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 MT
HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy MT
BTIG Assumes Lyra Therapeutics at Buy With $15 Price Target MT
BofA Securities Increases Price Target on Lyra Therapeutics to $15 From $13, Maintains Buy Rating MT
HC Wainwright Starts Lyra Therapeutics at Buy With $12 Price Target MT
BTIG Adjusts Price Target on Lyra Therapeutics to $20 From $24, Maintains Buy Rating MT
Cantor Fitzgerald Starts Lyra Therapeutics at Overweight With $15 Price Target MT
LYRA THERAPEUTICS : BofA securities Adjusts Lyra Therapeutics PT to $26 From $19, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.3255 USD
Average target price
4.5 USD
Spread / Average Target
+1,282.49%
High Price Target
11 USD
Spread / Highest target
+3,279.42%
Low Price Target
0.5 USD
Spread / Lowest Target
+53.61%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lyra Therapeutics, Inc.

HC Wainwright
Jefferies & Co.
BTIG
BofA Securities
Cantor Fitzgerald

Ratings for Lyra Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LYRA Stock
  4. Consensus Lyra Therapeutics, Inc.